NEW YORK – Molecular cancer testing firm Mainz Biomed announced on Tuesday that it has entered into a securities purchase agreement for a $6.0 million private placement with investor David Lazar.

纽约——分子癌症检测公司Mainz Biomed周二宣布，已与投资者David Lazar达成一项600万美元的私人配售证券购买协议。

The financing will be completed in two tranches of $3.0 million each through the issuance of convertible non-redeemable preferred stock. The first closing was completed on Feb. 13, and the second is expected to occur following receipt of required stockholder approvals and before April 15.

融资将通过发行可转换不可赎回优先股分两批完成，每批 300 万美元。首次交割已于 2 月 13 日完成，第二次交割预计将在收到所需的股东批准后且不晚于 4 月 15 日进行。

In conjunction with the financing, Mainz named David Lazar as chairman of its board of directors.

与融资同时进行，美因茨任命大卫·拉扎尔为主席。

Net proceeds from the placement will be used to fund ongoing operations, address outstanding liabilities, and preserve the company's ability to operate while it pursues strategic initiatives, the company said in a statement.

公司表示，此次配售的净收益将用于资助持续的运营、解决未偿债务，并在公司追求战略举措的同时保持其运营能力。

The company is transitioning its focus to developing its pancreatic cancer screening business in the US and is continuing to evaluate opportunities to sell its colorectal cancer (CRC) assets while winding down its German subsidiary. Mainz said it is currently in discussions with multiple parties interested in its CRC assets, which will allow it to significantly reduce its operating expenses and extend its runway..

公司正将其重点转向在美国开展胰腺癌筛查业务，同时继续评估出售其结直肠癌（CRC）资产的机会，并逐步关闭其德国子公司。美因茨表示，目前正在与多家对CRC资产感兴趣的各方进行谈判，这将使其能够大幅减少运营开支并延长资金储备期限。

Mainz's flagship product is ColoAlert, an early-detection test for CRC that is marketed

美因茨的旗舰产品是ColoAlert，这是一种用于CRC早期检测的测试，已上市销售。

across Europe

横跨欧洲

and

和

the UK

英国

. It also has developed PancAlert, an early-stage pancreatic cancer screening test based on PCR detection of molecular biomarkers in blood and stool samples.

它还开发了PancAlert，一种基于血液和粪便样本中分子生物标志物的PCR检测的早期胰腺癌筛查测试。

Last year, the firm

去年，该公司

began enrolling

开始注册

patients for its eAArly DETECT 2 study to further assess its next-generation RNA-based test for noninvasive colorectal cancer detection.

患者参与其eAArly DETECT 2研究，以进一步评估其下一代基于RNA的非侵入性结直肠癌检测测试。

'Our immediate focus is to continue to further develop and evaluate opportunities to grow our pancreatic screening program in the US and stabilize the business,' Lazar said in a statement. 'At the same time, we will be disciplined and thoughtful as we explore additional strategic alternatives that can unlock long-term value for stockholders.'.

“我们当前的重点是继续进一步开发和评估扩展我们在美国的胰腺筛查项目的机会，并稳定业务，”拉扎尔在一份声明中表示。“同时，我们将保持纪律性和深思熟虑，探索可以为股东释放长期价值的其他战略选择。”